Address untreated hearing loss when you notice hearing difficulty or someone raises a concern; do not wait for memory symptoms. Prompt assessment and management can support a dementia prevention plan, but hearing aids are not proven to prevent dementia for everyone. Here, untreated hearing loss means known or suspected hearing difficulty that is not being managed. The practical aim is to act early while keeping expectations about dementia prevention realistic.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Act on a concern, not a birthday
- Why hearing belongs in a brain-health plan
- What the ACHIEVE trial found
- Turn the evidence into a practical decision
Act on a concern, not a birthday
The key threshold is a hearing concern, not a particular age or cognitive diagnosis. The World Health Organization's hearing-loss guidance says identified hearing loss should be addressed as early as possible to limit its adverse effects. Routine screening is a separate question.
The U.S. Preventive Services Task Force finds insufficient evidence to recommend for or against screening adults aged 50 and older who have no symptoms. That uncertainty should not delay evaluation when difficulty is already noticeable.
Why hearing belongs in a brain-health plan
WHO identifies hearing loss as a dementia risk factor. It also reports that unaddressed hearing loss is associated with faster cognitive decline and increased dementia risk. An association does not prove that hearing loss causes dementia or that treating it will prevent dementia.
Several factors may contribute to the relationship, and the available evidence does not support a universal prevention promise. WHO's 2026 dementia-risk-reduction guidance therefore says hearing aids "may" be offered as part of risk-reduction strategies. That wording supports considering treatment without presenting it as a guaranteed safeguard.
What the ACHIEVE trial found
The ACHIEVE randomized trial published in The Lancet included 977 dementia-free adults aged 70 to 84 with untreated mild-to-moderate hearing loss. Over three years, the hearing intervention did not significantly reduce global cognitive decline across all participants compared with health education. The intervention involved more than receiving a device. Participants received hearing aids, audiologic counseling, and self-management support, so the trial did not test hearing aids in isolation.
A prespecified result was more encouraging for 238 participants from the ARIC cardiovascular cohort. According to the Alzheimer's Association's ACHIEVE report, the intervention slowed cognitive decline by 48% over three years in this higher-risk group. That figure does not mean hearing aids reduced dementia diagnoses by 48%. It describes slower cognitive decline in older adults who had more cognitive-risk factors and lower cognition at the start. The healthier, lower-risk volunteer group did not show the same benefit.
Turn the evidence into a practical decision
Begin with a hearing evaluation when you notice difficulty or another person raises a concern. If treatment is recommended, discuss the full management approach rather than viewing a hearing aid as a stand-alone dementia intervention. Set expectations according to the evidence.
Treatment may be especially relevant for an older adult already at elevated risk of cognitive decline, but it remains appropriate to address hearing difficulty for its own adverse effects. For someone without hearing symptoms, routine screening remains an individual discussion because the evidence is insufficient for a universal recommendation. For someone with noticeable difficulty, arrange an assessment now rather than waiting for cognitive problems.
